A multicenter prospective study on the management of hepatoblastoma in children: a report from the Chinese Children's Cancer Group
CONCLUSIONS: The survival outcome of HB children has dramatically improved since the implementation of CCCG-HB-2016 therapy. Age ≥ 8 years, R + , and E + were independent risk factors for prognosis. Patients with a declining AFP > 75% after the first two cycles of neoadjuvant chemotherapy had better EFS and OS.PMID:37770810 | DOI:10.1007/s12519-023-00750-6
Source: World Journal of Pediatrics : WJP - Category: Pediatrics Authors: Meng-Jie Tang Xiao-Li Ma Xiang-Ling He Wei-Hua Pan Xiao-Hong Zhang Sha-Yi Jiang Ju Gao Fu Li Wei Yao Song Gu Wei-Ling Zhang Qiang Zhao Shi-Hao Huang Yong-Jun Fang Wei Liu Hui-Zhong Niu Chun-Mei Wang Li-Rong Sun Hui Gao Yun-Peng Dai Shun-Gen Huang Zhi-Yong Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Children | China Health | Hepatoblastoma | Men | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pediatrics | Study